 Connection
Jeffrey Swigris to Adult
This is a "connection" page, showing publications Jeffrey Swigris has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.364 |
|
|
|
-
Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, Swigris JJ. Informal caregivers experience of supplemental oxygen in pulmonary fibrosis. Health Qual Life Outcomes. 2017 Jul 01; 15(1):133.
Score: 0.032
-
Walker TD, Desserich J, Albright K, Wamboldt FS, Belkin A, Fier K, Swigris JJ. Development of ATAQ-LAM: a tool to assess quality of life in Lymphangioleiomyomatosis. Health Qual Life Outcomes. 2015 Jul 30; 13:112.
Score: 0.028
-
Belkin A, Albright K, Fier K, Desserich J, Swigris JJ. "Getting stuck with LAM": patients perspectives on living with lymphangioleiomyomatosis. Health Qual Life Outcomes. 2014 May 21; 12:79.
Score: 0.026
-
Fern?ndez P?rez ER, Krishnamoorthy M, Brown KK, Huie TJ, Fischer A, Solomon JJ, Meehan RT, Olson AL, Achcar RD, Swigris JJ. FEV1 over time in patients with connective tissue disease-related bronchiolitis. Respir Med. 2013 Jun; 107(6):883-9.
Score: 0.024
-
Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012 Jul; 106(7):1040-7.
Score: 0.023
-
Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med. 2012 Mar; 33(1):41-50.
Score: 0.022
-
Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1524-30.
Score: 0.021
-
Li HY, Cosgrove GP, Swigris JJ. Dyspnea in a 43-year-old woman with polycystic kidney disease. Chest. 2009 Jan; 135(1):238-243.
Score: 0.018
-
Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005 Oct 07; 3:61.
Score: 0.014
-
Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: a narrative review. Chest. 2002 Dec; 122(6):2150-64.
Score: 0.012
-
Suzuki A, Kondoh Y, Swigris JJ, Matsuda T, Kimura T, Kataoka K, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. Respir Med. 2019 04; 150:15-20.
Score: 0.009
-
Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. 2018; 96(6):514-524.
Score: 0.009
-
Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. J Rheumatol. 2018 02; 45(2):235-241.
Score: 0.008
-
Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 09 15; 196(6):756-761.
Score: 0.008
-
Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respir Med. 2016 10; 119:150-154.
Score: 0.008
-
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.008
-
Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, Truong TQ, Brown KK, Achcar RD, Olson AL, Cox CW, Kligerman SJ, Curran-Everett D, Fern?ndez P?rez ER. Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease. Ann Am Thorac Soc. 2016 07; 13(7):1042-9.
Score: 0.008
-
Chartrand S, Swigris JJ, Peykova L, Chung J, Fischer A. A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. J Rheumatol. 2016 05; 43(5):887-92.
Score: 0.007
-
Liu H, Patel D, Welch AM, Wilson C, Mroz MM, Li L, Rose CS, Van Dyke M, Swigris JJ, Hamzeh N, Maier LA. Association Between Occupational Exposures and Sarcoidosis: An Analysis From Death Certificates in the United States, 1988-1999. Chest. 2016 08; 150(2):289-98.
Score: 0.007
-
Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016 Jan; 47(1):243-53.
Score: 0.007
-
Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M. Benefits of Physical Training in Sarcoidosis. Lung. 2015 Oct; 193(5):701-8.
Score: 0.007
-
Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest. 2015 Jul; 148(1):196-201.
Score: 0.007
-
Strookappe B, Elfferich M, Swigris J, Verschoof A, Veschakelen J, Knevel T, Drent M. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22; 32(1):43-52.
Score: 0.007
-
Olson AL, Swigris JJ, Belkin A, Hannen L, Yagihashi K, Schenkman M, Brown KK. Physical functional capacity in idiopathic pulmonary fibrosis: performance characteristics of the continuous-scale physical function performance test. Expert Rev Respir Med. 2015 Jun; 9(3):361-7.
Score: 0.007
-
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
Score: 0.007
-
Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med. 2013 Aug; 1(6):445-52.
Score: 0.006
-
Yorke J, Russell AM, Swigris J, Shuldham C, Haigh C, Rochnia N, Hoyle J, Jones PW. Assessment of dyspnea in asthma: validation of The Dyspnea-12. J Asthma. 2011 Aug; 48(6):602-8.
Score: 0.005
-
Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, Frankel SK, Fernandez-Perez ER, Gillis JZ, Brown KK. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009 Nov; 103(11):1719-24.
Score: 0.005
-
Fischer A, Swigris JJ, du Bois RM, Groshong SD, Cool CD, Sahin H, Lynch DA, Gillis JZ, Cohen MD, Meehan RT, Brown KK. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest. 2009 Oct; 136(4):1072-1078.
Score: 0.005
-
Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, Curran-Everett D, Gillis JZ, Meehan RT, Brown KK. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008 Sep; 134(3):601-605.
Score: 0.004
-
Fischer A, Misumi S, Curran-Everett D, Meehan RT, Ulrich SK, Swigris JJ, Frankel SK, Cosgrove GP, Lynch DA, Brown KK. Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease. Chest. 2007 Apr; 131(4):988-92.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|